Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Calm in a room: can sensory therapy soothe the mind?

NCT ID NCT07748078

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial tests whether Snoezelen therapy—a calming, multisensory experience using lights, sounds, and textures—can improve health in adults with schizophrenia (including those needing institutional care) and women with alcohol dependence. Participants will attend 30-minute sessions twice a week for 6 or 12 weeks. Researchers will measure changes in cognition, mood, anxiety, life satisfaction, daily functioning, and certain blood markers to see if this gentle therapy offers benefits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Snoezelen therapy, a multisensory relaxation intervention involving controlled visual, auditory, and tactile stimuli in a calming environment
What this could lead to
If effective, Snoezelen therapy could offer a drug-free, non-invasive way to ease symptoms and improve quality of life for people with schizophrenia or alcohol dependence.
What could go wrong
This is an early-stage trial with a modest number of participants, and results may not generalize. The therapy is supportive, not curative, and its benefits may vary widely between individuals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. Adults suffering from schizophrenia requiring permanent institutional care, N=40 Inclusion criteria: * women and men aged ≥ 18 years, * consent of the patient or legal guardian to participate in the study, * schizophrenia clinically confirmed for at least 5 years, with predominance of negative symptoms, * stable drug therapy (treatment unchanged for at least 3 months) * ability to understand and follow the therapist's instructions, * functional ability of everyday life on the Barthel scale below 40 points, Exclusion criteria: * lack of consent to participate in the study; * pregnancy; * general contraindications (acute inflammatory and febrile diseases, venous thrombosis, unstable arterial hypertension, early condition after contrast computed tomography, early condition after lumbar puncture, general serious condition of the patient); * unstable or untreated epilepsy, based on EEG; * exacerbation of the main disease (acute psychosis, severe anxiety, tendency to active aggression, etc.); * active cancer disease; * diseases of the nervous system (neuropathies, stroke, damage to the cerebellum, labyrinth, Parkinson's disease) causing altered sensitivity to stimuli; * diseases and illnesses of the musculoskeletal system that disturb the body's balance and the mobility of the limbs. 2. Adults (men) suffering from schizophrenia, N=40 Inclusion criteria: * men aged ≥ 18 years, * consent of the patient or legal guardian to participate in the study, * clinically confirmed schizophrenia with predominance of negative symptoms, * stable drug therapy (treatment unchanged for at least 1 month), * ability to understand and follow the therapist's instructions, * functional ability of everyday life on the Barthel scale above 40 points, Exclusion criteria: * lack of consent to participate in the study; * general contraindications (acute inflammatory and febrile diseases, venous thrombosis, unstable arterial hypertension, early condition after contrast computed tomography, early condition after lumbar puncture, general serious condition of the patient); * unstable or untreated epilepsy, based on EEG; * exacerbation of the main disease (acute psychosis, severe anxiety, tendency to active aggression, etc.); * active cancer disease; * diseases of the nervous system (neuropathies, stroke, damage to the cerebellum, labyrinth, Parkinson's disease) causing altered sensitivity to stimuli; diseases and illnesses of the musculoskeletal system disturbing body balance and limb mobility. 3. Adults (women) addicted to alcohol, N= 60 Inclusion criteria: * female gender; * age ≥ 18 years; * consent of the patient or legal guardian to participate in the study; * alcohol dependence syndrome (F10.2 according to ICD-10); * history of depressive and anxiety symptoms; * ability to understand and follow the therapist's instructions; * functional ability of everyday life on the Barthel scale above 40 points. Exclusion criteria: * lack of consent to participate in the study; * pregnancy; * psychoactive substances other than alcohol; * exacerbation of the main disease (acute psychosis, severe anxiety, tendency to active aggression, etc.); * mental illnesses other than depression and anxiety disorders; * psychotic diseases (F20- schizophrenia and other schizophrenic disorders); * general contraindications (acute inflammatory and febrile diseases, venous thrombosis, unstable arterial hypertension, early condition after contrast computed tomography, early condition after lumbar puncture, general serious condition of the patient); * unstable or untreated epilepsy, based on EEG; * active cancer disease; * diseases of the nervous system (neuropathies, stroke, damage to the cerebellum, labyrinth, Parkinson's disease) causing altered sensitivity to stimuli; * severe cognitive impairment; * diagnosis of autism and ADHD; * PTSD; * intellectual disability (diagnosis F70 - F79); * diseases and illnesses of the musculoskeletal system that disturb the body's balance and the mobility of the limbs.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alcohol dependence (primary condition) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinical Psychiatric Hospital SPZOZ in Rybnik, Poland

    Rybnik, Silesian Voivodeship, 44-200, Poland

  • Jerzy Kukuczka Academy of Physical Education in Katowice, Poland

    Katowice, Silesian Voivodeship, 40-065, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.